Baidu
map

NEJM:Nubeqa(darolutamide)显著延长非转移性前列腺癌患者的寿命!

2020-09-10 Allan MedSci原创

与安慰剂联合ADT相比,接受darolutamide联合雄激素剥夺疗法(ADT)的男性表现出OS的显著改善,死亡风险降低了31%。

ARAMIS研究显示,与安慰剂联合雄激素剥夺疗法(ADT)相比,接受Nubeqa(darolutamide)联合ADT的非转移性去势抵抗性前列腺癌(nmCRPC)男性患者的总生存期(OS)得到显著提高(HR = 0.69,95%CI 0.53-0.88,p = 0.003),所有其他次要终点也得到显著改善。总体而言,不良事件发生率与单独使用ADT一致。这些结果近日发表于《新英格兰医学杂志,NEJM》之上。

ARAMIS研究负责人Karim Fizazi博士说:“通过正在进行的研究,我们已经确定了将治疗重点放在延长nmCRPC男性寿命和减少副作用等方面”。

与安慰剂联合ADT相比,接受darolutamide联合雄激素剥夺疗法(ADT)的男性表现出OS的显著改善,死亡风险降低了31%(HR = 0.69,95%CI 0.53-0.88,p = 0.003)。尽管安慰剂组中超过一半(56%)的患者(554名患者中的309名)在数据分析截止时(2019年11月15日)接受了后续的darolutamide或其他延长生命的治疗,但仍能观察到OS获益。

 

原始出处:

https://www.firstwordpharma.com/node/1756199?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
    2020-09-10 ms3000001667701305

    1111111111111111111111

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
    2020-09-10 ms3000001667701305

    1

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1819685, encodeId=28d6181968575, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 14 16:25:37 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Sep 15 00:25:37 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976582, encodeId=cc1219e65828b, content=<a href='/topic/show?id=29a09340656' target=_blank style='color:#2F92EE;'>#转移性前列腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93406, encryptionId=29a09340656, topicName=转移性前列腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Oct 23 19:25:37 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5704, encryptionId=48e55e0461, topicName=darolutamide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ab13776446, createdName=yangcx0916, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589475, encodeId=73ce15894e51d, content=<a href='/topic/show?id=74ff99695f0' target=_blank style='color:#2F92EE;'>#非转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99695, encryptionId=74ff99695f0, topicName=非转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=022b17724229, createdName=jinweidong, createdTime=Sat Sep 12 00:25:37 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884308, encodeId=f16088430820, content=1111111111111111111111, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:58:13 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884296, encodeId=df84884296b9, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210107/b1a3bfcb6b27441abc5b407311125835/411bf7ab863e43f0a41bb263699b3962.jpg, createdBy=1e5e5409476, createdName=ms3000001667701305, createdTime=Thu Sep 10 20:34:14 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035410, encodeId=a679103541001, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 10 12:25:37 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
    2020-09-10 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

2017 IOF立场声明:非转移性前列腺癌患者脆性骨折的预防

2017年5月,国际骨质疏松协会(IOF)发布了非转移性前列腺癌患者脆性骨折的预防的立场声明,激素阻断治疗常用于非转移性前列腺癌的首要和辅助治疗,本文的主要内容针对非转移性前列腺癌肿瘤治疗依赖性骨病的相关证据以及康骨质疏松治疗的疗效等。

拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权,用于治疗非转移性前列腺癌

欧盟委员会已授予拜耳(Bayer)口服非甾体雄激素受体拮抗剂Nubeqa(darolutamide)的销售许可,用于治疗非转移性去势抵抗性前列腺癌(nmCRPC)的男性患者。

2019ESMO-Asia:Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间

根据在2019年欧洲医学肿瘤学会(ESMO)亚洲大会上发表的一项研究,Darolutamide延缓了非转移性去势抵抗性前列腺癌患者的疾病进展和开始化疗的时间。

拓展阅读

Eur Urol Oncol:根治性前列腺切除术对根据STAMPEDE标准选择的高风险非转移性前列腺癌男性生存率的影响

比利时鲁汶大学医院等机构的研究人员研究证实,手术仍然是STAMPEDE高危PCa患者的可行治疗方案。

J Clin Oncol:放疗(RT)和雄激素剥夺疗法(ADT)联合或不联合多西他赛治疗非转移性的不良风险前列腺癌的疗效:一项前瞻性随机研究

对于非转移性的不良风险前列腺癌患者,在放疗(RT)和雄激素剥夺疗法(ADT)的基础上加入多西他赛并不能延长OS。

拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权,用于治疗非转移性前列腺癌

欧盟委员会已授予拜耳(Bayer)口服非甾体雄激素受体拮抗剂Nubeqa(darolutamide)的销售许可,用于治疗非转移性去势抵抗性前列腺癌(nmCRPC)的男性患者。

2019ESMO-Asia:Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间

根据在2019年欧洲医学肿瘤学会(ESMO)亚洲大会上发表的一项研究,Darolutamide延缓了非转移性去势抵抗性前列腺癌患者的疾病进展和开始化疗的时间。

2017 IOF立场声明:非转移性前列腺癌患者脆性骨折的预防

2017年5月,国际骨质疏松协会(IOF)发布了非转移性前列腺癌患者脆性骨折的预防的立场声明,激素阻断治疗常用于非转移性前列腺癌的首要和辅助治疗,本文的主要内容针对非转移性前列腺癌肿瘤治疗依赖性骨病的相关证据以及康骨质疏松治疗的疗效等。

Baidu
map
Baidu
map
Baidu
map